Home » Australia’s TGA Set To Implement More Streamlined Review Process for Pharmaceuticals
Australia’s TGA Set To Implement More Streamlined Review Process for Pharmaceuticals
September 16, 2010
Starting Nov. 1, manufacturers making Category 1 and 2 prescription drug submissions on or after Feb. 1, 2011, and using Australia’s streamlined submission process must file a presubmission planning form (PPF), the Therapeutic Goods Administration (TGA) says in recent guidance for industry.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor